r availability of competitive products or
technologies, the future ability of Verenium to enter into and/or maintain
collaboration and joint venture agreements and licenses, changes in the
U.S. or global energy markets and risks and other uncertainties more fully
described in the Company's filings with the Securities and Exchange
Commission, including, but not limited to, the Company's annual report on
Form 10-K for the year ended December 31, 2007 and the Company's Form 8-K
filed on April 8, 2008. These forward-looking statements speak only as of
the date hereof. The Company expressly disclaims any intent or obligation
to update these forward-looking statements.
Contacts:
Kelly Lindenboom
Vice President, Corporate Communications
617-674-5335
kelly.lindenboom@verenium.com
Sarah Carmody
Sr. Corporate Communications Associate
617-674-5357
sarah.carmody@verenium.com
Selected Financial Information
Condensed Consolidated Loss from Operations
(unaudited, in thousands)
Three Months Ended March 31,
2008 2007
Revenues:
Product $11,201 $5,352
Collaborative 3,475 4,735
Grant 559 1,221
Total revenues 15,235 11,308
Cost of product revenues 7,877 4,892
Product gross profit 3,324 460
Operating expenses:
Research and development 14,861 11,639
Se
'/>"/>
SOURCE Verenium Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference2.
Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy3.
Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference4.
Verenium Advances Its Development Work With Cargill on a New Food-Related Product5.
Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference6.
ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance7.
United Therapeutics Reports First Quarter 2008 Financial Results8.
Endocare Reports 2008 First Quarter Financial Results9.
AMICAS Reports Financial Results for the First Quarter Ended March 31, 200810.
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase11.
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights